{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:23:35Z","timestamp":1790169815692,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.mayocp.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:20:03Z","timestamp":1781911203000},"page":"1482-1496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association Between Angiotensin Receptor Blocker Use and Cardiovascular Outcomes Compared With Angiotensin-Converting Enzyme Inhibitors in Patients With Atherosclerotic Cardiovascular Disease"],"prefix":"10.1016","volume":"101","author":[{"given":"Jheng-Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Wei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1723-828X","authenticated-orcid":false,"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2026.05.016_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100634","article-title":"Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US Adults, 1999-2018","volume":"17","author":"Zhang","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.016_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjqcco\/qcy058","article-title":"Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data","volume":"5","author":"Lindh","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"6","key":"10.1016\/j.mayocp.2026.05.016_bib3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/eurjpc\/zwae038","article-title":"Impact of the 2021 European Society for Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease","volume":"31","author":"Holtrop","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"34","key":"10.1016\/j.mayocp.2026.05.016_bib4","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"2a","key":"10.1016\/j.mayocp.2026.05.016_bib5","doi-asserted-by":"crossref","first-page":"11A","DOI":"10.1016\/S0002-9149(01)02322-0","article-title":"Angiotensin II and trials of cardiovascular outcomes","volume":"89","author":"Sleight","year":"2002","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.016_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.016_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"issue":"9386","key":"10.1016\/j.mayocp.2026.05.016_bib8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.016_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.016_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"10.1016\/j.mayocp.2026.05.016_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.mayocp.2026.05.016_bib12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2026.05.016_bib13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/heartjnl-2016-310705","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk","volume":"103","author":"Potier","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.mayocp.2026.05.016_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2016.04.132","article-title":"ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure \u2014 a network meta-analysis","volume":"217","author":"Ricci","year":"2016","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.016_bib15","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/HYPERTENSIONAHA.125.25549","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: multidatabase target trial emulation studies","volume":"82","author":"Xie","year":"2025","journal-title":"Hypertension"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.05.016_bib16","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.016_bib17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaf014","article-title":"Prognostic benefit of GLP-1 RA addition to SGLT2i in patients with ASCVD and heart failure: a cohort study","volume":"11","author":"Chen","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.016_bib18","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1038\/s41467-025-59616-2","article-title":"Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study","volume":"16","author":"Lin","year":"2025","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.mayocp.2026.05.016_bib19","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"issue":"41","key":"10.1016\/j.mayocp.2026.05.016_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000045180","article-title":"Early versus late oral anticoagulation after mild to moderate AIS in AF patients: insights from real-world data","volume":"104","author":"Wu","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.mayocp.2026.05.016_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112918","article-title":"Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM","volume":"229","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.016_bib22","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.016_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.016_bib24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.016_bib25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3904\/kjim.2018.312","article-title":"Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases","volume":"35","author":"Choi","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.05.016_bib26","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.3390\/cells10102699","article-title":"The role of sodium glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease: a narrative review of potential mechanisms","volume":"10","author":"Barraclough","year":"2021","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.mayocp.2026.05.016_bib27","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.016_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ajh\/hpab108","article-title":"Renin angiotensin blockers and cardiac protection: from basis to clinical trials","volume":"35","author":"L\u00e9vy","year":"2022","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.016_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13280","article-title":"Anti-fibrotic mechanisms of angiotensin AT(2)\u2013receptor stimulation","volume":"227","author":"Sumners","year":"2019","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.mayocp.2026.05.016_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116062","article-title":"Angiotensin AT(2) receptors reduce inflammation and fibrosis in cardiovascular remodeling","volume":"222","author":"Kaschina","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.016_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.intimp.2007.06.012","article-title":"Angiotensin II\u2013induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide","volume":"8","author":"Yayama","year":"2008","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.016_bib32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2026.05.016_bib33","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.016_bib34","article-title":"The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone","volume":"58","author":"Schjoedt","year":"2011","journal-title":"Dan Med Bull"},{"issue":"18","key":"10.1016\/j.mayocp.2026.05.016_bib35","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.4244\/EIJ-D-24-00992","article-title":"Antithrombotic therapy in complex percutaneous coronary intervention","volume":"21","author":"Castiello","year":"2025","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.016_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thx.51.2.199","article-title":"Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P","volume":"51","author":"Tomaki","year":"1996","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.016_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ihj.2020.08.007","article-title":"ACEI-induced cough: a review of current evidence and its practical implications for optimal CV risk reduction","volume":"72","author":"Pinto","year":"2020","journal-title":"Indian Heart J"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.016_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF03261835","article-title":"Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis","volume":"12","author":"Caldeira","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"issue":"16","key":"10.1016\/j.mayocp.2026.05.016_bib39","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.016_bib40","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.mayocp.2023.10.005","article-title":"Real-world evidence for causal inference \u2014 are we ready?","volume":"98","author":"Strauss","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.016_bib41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJMsb1901642","article-title":"The magic of randomization versus the myth of real-world evidence","volume":"382","author":"Collins","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626185887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626185887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:38:44Z","timestamp":1788244724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626185887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0025619626185887"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.05.016","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Angiotensin Receptor Blocker Use and Cardiovascular Outcomes Compared With Angiotensin-Converting Enzyme Inhibitors in Patients With Atherosclerotic Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}